Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
US Government Will Fund Up To $268.8m In Production Site Upgrades
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
You may also be interested in...
Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.
Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection
The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.
Coronavirus Update: How Vaccines Stack Up Against Variants So Far
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.